- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
The LUME-Lung Phase III programme for BIBF 1120*, comprises two multinational trials. These placebo-controlled studies are investigating the safety and efficacy of BIBF 1120* in NSCLC patients after first line chemotherapy treatment. In the LUME-Lung 1 trial, which includes patients with all histologies, BIBF 1120* is administered in combination with standard chemotherapy agent docetaxel. The last patient was recruited to LUME-Lung 1 in early February 2011. In the LUME-Lung 2 trial, which includes only patients with non-squamous cell carcinomas, BIBF 1120* is administered in combination with pemetrexed. Approximately 2,600 patients will be enrolled, making this one of the largest Phase III study programmes in this NSCLC patient population to date.
* BIBF 1120 is an investigational compound. Its safety and efficacy have not yet been fully established.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
